当前位置:首页 - 行情中心 - 泰林生物(300813) - 财务分析 - 现金流量表

泰林生物

(300813)

  

流通市值:18.51亿  总市值:26.35亿
流通股本:8512.61万   总股本:1.21亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金191,499,433.1478,884,224.82337,098,567.74235,266,522.34
  收到的税费返还4,539,251.742,421,682.59,547,174.166,583,514.93
  收到其他与经营活动有关的现金5,639,562.497,469,390.529,117,118.5913,699,726.15
  经营活动现金流入小计201,678,247.3788,775,297.84355,762,860.49255,549,763.42
  购买商品、接受劳务支付的现金76,247,301.0127,065,991.64111,933,636.0780,410,879.06
  支付给职工以及为职工支付的现金80,701,070.4747,095,100.53138,395,438.37106,489,360.37
  支付的各项税费12,915,916.828,620,321.8623,584,464.0822,093,598.19
  支付其他与经营活动有关的现金10,713,389.599,550,894.734,127,312.5331,696,769.81
  经营活动现金流出小计180,577,677.8992,332,308.73308,040,851.05240,690,607.43
  经营活动产生的现金流量净额21,100,569.48-3,557,010.8947,722,009.4414,859,155.99
二、投资活动产生的现金流量:
  收回投资收到的现金---586,145.83
  取得投资收益收到的现金--9,384,212.49-
  收到的其他与投资活动有关的现金817,940,739.86361,909,860.581,241,004,000762,697,678.17
  投资活动现金流入小计817,940,739.86361,909,860.581,250,388,212.49763,283,824
  购建固定资产、无形资产和其他长期资产支付的现金24,582,304.268,774,544.546,885,597.3318,686,237.12
  投资支付的现金--2,000,000-
  支付其他与投资活动有关的现金701,800,000283,000,0001,199,100,000726,000,000
  投资活动现金流出小计726,382,304.26291,774,544.51,247,985,597.33744,686,237.12
  投资活动产生的现金流量净额91,558,435.670,135,316.082,402,615.1618,597,586.88
三、筹资活动产生的现金流量:
  收到其他与筹资活动有关的现金--11,174,00011,174,000
  筹资活动现金流入平衡项目--00
  筹资活动现金流入小计--11,174,00011,174,000
  偿还债务支付的现金--3,669,656.413,669,656.41
  分配股利、利润或偿付利息支付的现金3,599,437.47-24,719,669.2224,213,792.13
  其中:子公司支付给少数股东的股利、利润--479,825.42-
  支付其他与筹资活动有关的现金32,285,577.5147,169.8123,509,544.3123,675,515.56
  筹资活动现金流出小计35,885,014.9847,169.8151,898,869.9451,558,964.1
  筹资活动产生的现金流量净额-35,885,014.98-47,169.81-40,724,869.94-40,384,964.1
四、汇率变动对现金及现金等价物的影响-455,933.89-422,963.92-732,533.59-375,657.52
五、现金及现金等价物净增加额76,318,056.2166,108,171.468,667,221.07-7,303,878.75
  加:期初现金及现金等价物余额78,545,303.5378,545,303.5369,878,082.4669,878,082.46
  期末现金及现金等价物余额154,863,359.74144,653,474.9978,545,303.5362,574,203.71
补充资料:
  净利润20,372,823.69-16,286,074.7-
  资产减值准备886,249.41-3,963,381.82-
  固定资产和投资性房地产折旧7,893,215.04-15,919,807.65-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧7,893,215.04-15,919,807.65-
  无形资产摊销397,880.46-749,661.96-
  长期待摊费用摊销2,147,909.06-4,160,512.79-
  固定资产报废损失176,221.93-371,037.57-
  公允价值变动损失---20,441.21-
  财务费用-800,082.83--2,274,959.57-
  投资损失-1,641,315.01--4,358,519.68-
  递延所得税-350,073.92--929,625.94-
  其中:递延所得税资产减少10,895.81--81,679-
    递延所得税负债增加-360,969.73--847,946.94-
  存货的减少-11,117,465.23-13,861,292.84-
  经营性应收项目的减少-1,348,502.01--1,227,940.18-
  经营性应付项目的增加2,850,370.73--4,400,013.8-
  其他1,633,338.16-5,621,740.49-
  现金的期末余额154,863,359.74-78,545,303.53-
  减:现金的期初余额78,545,303.53-69,878,082.46-
  现金及现金等价物的净增加额76,318,056.21-8,667,221.07-
公告日期2026-08-272026-04-302026-03-272025-10-27
审计意见(境内)标准无保留意见
TOP↑